BACKGROUND Previous exposures to flu and subsequent immune responses may impact on 2009/2010 pandemic flu vaccine responses and clinical symptoms upon infection with the 2009 pandemic H1N1 influenza strain. Qualitative and quantitative differences in humoral and cellular immune responses associated with the flu vaccination in 2009/2010 (pandemic H1N1 vaccine) and natural infection have not yet ...

In England, during pandemic 2009 H1N1, vaccine efficacy and immunogenicity population studies in priority groups were rolled out in parallel to evaluate the pandemic vaccination programme. This provided a unique opportunity to compare immunogenicity and clinical protection in the same population and thus provide insights into the correlates of protection for the pandemic H1N1 2009 vaccine in ri...

The robust immune response to a single dose of pandemic 2009 H1N1 vaccine suggests that a large segment of the population has been previously primed. We evaluated the effect of seasonal (s) H1N1 infection, s-trivalent inactivated vaccine (s-TIV), and trivalent s-live attenuated influenza vaccine (s-LAIV) before immunization with a pandemic live attenuated influenza vaccine (p-LAIV) in mice. We ...

Background Long-term persistence of immune response and safety of two doses of an A/California/07/2009 H1N1 pandemic influenza vaccine adjuvanted with AS03 (an α-tocopherol oil-in-water emulsion-based Adjuvant System) administered 21 d apart was evaluated in Japanese adults [NCT00989612]. Methods One-hundred healthy subjects aged 20-64 y (stratified [1:1] into two age strata 20-40 y and 41-...

Tomorrow, the world could face a pandemic. It could be due to H5N1 avian influenza—experts warn that it is just a matter of time—or a different influenza strain, an unknown pathogen, or a bioterrorist attack. In all cases, biological scientists face the challenge of characterizing the pathogen and determining how to control it. Their scientific judgments and public statements will shape the glo...

The debate about the management of pandemic (H1N1) 2009 is heating up as a number of government-appointed committees and private interest groups start to make their assessments available. On one hand is concern that the severity of the pandemic was overestimated and resources were wasted; on the other hand are criticisms that a necessary immunization program was woefully inadequate and plagued ...

BACKGROUND Antiviral agents could play a significant role in the response to a future influenza pandemic, especially if an effective vaccine is unavailable. There is, however, a limited availability of antiviral drugs, as was the case during the A/Fujian(H3N2) epidemic in the 2003-2004 season. There are major differences among the available antiviral agents in terms of clinical pharmacology, ad...

The outcome of viral infections depends on a complex set of interactions between the viruses and their hosts. Particularly, viral infection triggers specific signaling programs within the infected cells that results in substantial changes in host gene expression. While some of these changes might be beneficial for viral replication, others represent the induction of a host antiviral response. I...

1 Coordinator, Risk Containment, Mapping and Drug Resistance, Communicable Diseases Surveillance and Response, World Health Organization, 1211 Geneva 27, Switzerland (email: [email protected]). Correspondence should be sent to this author. 2 Project Leader, Global Influenza Programme, Communicable Diseases Surveillance and Response, World Health Organization, Geneva, Switzerland. Ref. No. 04-012...

The threat of an H5N1 influenza virus (avian flu) pandemic is substantial. The success of the current U.S. influenza pandemic response plan depends on effective coordination among state and local public health authorities and individual health care providers. This article is a summary of a public policy paper developed by the American College of Physicians to address issues in the U.S. Departme...